Evidence map›Paper›PMID 26749309›Full record

ArticleAmerican journal of human genetics2016

Autosomal-Dominant Corneal Endothelial Dystrophies CHED1 and PPCD1 Are Allelic Disorders Caused by Non-coding Mutations in the Promoter of OVOL2.

Alice E Davidson, Petra Liskova, Cerys J Evans, Lubica Dudakova, Lenka Nosková, Nikolas Pontikos, Hana Hartmannová, Kateřina Hodaňová, Viktor Stránecký, Zbyněk Kozmík and 16 more

Open access · hybridAbstract read
In one paragraph

Article in American journal of human genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 78 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Disruption ofHuman mutation · 2024
    Article
  5. Review
  6. Role of non-coding variants in cardiovascular disease.Journal of cellular and molecular medicine · 2023
    Review
  7. Article
  8. Autophagy in the normal and diseased cornea.Experimental eye research · 2022
    Review
  9. Article
  10. Update on the genetics of corneal endothelial dystrophies.Indian journal of ophthalmology · 2022
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Diseases of the corneal endothelium.Experimental eye research · 2021
    Review
  16. Review
  17. Article
  18. Article
  19. Corneal dystrophies.Nature reviews. Disease primers · 2020
    Review
  20. CUGC for posterior polymorphous corneal dystrophy (PPCD).European journal of human genetics : EJHG · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 6 institutions in 2 countries.

Alice E DavidsonUCL Institute of Ophthalmology, University College London, London EC1V 9EL, UK.
Petra LiskovaUCL Institute of Ophthalmology, University College London, London EC1V 9EL, UK; Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Ke Karlovu 2, Prague 128 08, Czech Republic; Department of Ophthalmology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, U Nemocnice 2, Prague 128 08, Czech Republic. Electronic address: petra.liskova@lf1.cuni.cz.
Cerys J EvansUCL Institute of Ophthalmology, University College London, London EC1V 9EL, UK.
Lubica DudakovaInstitute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Ke Karlovu 2, Prague 128 08, Czech Republic.
Lenka NoskováInstitute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Ke Karlovu 2, Prague 128 08, Czech Republic.
Nikolas PontikosUCL Institute of Ophthalmology, University College London, London EC1V 9EL, UK; UCL Genetics Institute, University College London, London WC1E 6BT, UK.
Hana HartmannováInstitute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Ke Karlovu 2, Prague 128 08, Czech Republic.
Kateřina HodaňováInstitute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Ke Karlovu 2, Prague 128 08, Czech Republic.
Viktor StráneckýInstitute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Ke Karlovu 2, Prague 128 08, Czech Republic.
Zbyněk KozmíkInstitute of Molecular Genetics, Vídeňská 1083, Prague 142 20, Czech Republic.
Hannah J LevisUCL Institute of Ophthalmology, University College London, London EC1V 9EL, UK.
Nwamaka IdigoUCL Institute of Ophthalmology, University College London, London EC1V 9EL, UK.
Noriaki SasaiUCL Institute of Ophthalmology, University College London, London EC1V 9EL, UK.
Geoffrey J MaherWeatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.
James BellinghamUCL Institute of Ophthalmology, University College London, London EC1V 9EL, UK.
Neyme VeliMoorfields Eye Hospital, London EC1V 2PD, UK.
Neil D EbenezerUCL Institute of Ophthalmology, University College London, London EC1V 9EL, UK.
Michael E CheethamUCL Institute of Ophthalmology, University College London, London EC1V 9EL, UK.
Julie T DanielsUCL Institute of Ophthalmology, University College London, London EC1V 9EL, UK.
Caroline M H ThaungUCL Institute of Ophthalmology, University College London, London EC1V 9EL, UK; Moorfields Eye Hospital, London EC1V 2PD, UK.
Katerina JirsovaInstitute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Ke Karlovu 2, Prague 128 08, Czech Republic.
Vincent PlagnolUCL Genetics Institute, University College London, London WC1E 6BT, UK.
Martin FilipecEuropean Eye Clinic Lexum, Antala Staška 1670/80, Prague 140 00, Czech Republic.
Stanislav KmochInstitute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Ke Karlovu 2, Prague 128 08, Czech Republic.
Stephen J TuftUCL Institute of Ophthalmology, University College London, London EC1V 9EL, UK; Moorfields Eye Hospital, London EC1V 2PD, UK.
Alison J HardcastleUCL Institute of Ophthalmology, University College London, London EC1V 9EL, UK. Electronic address: a.hardcastle@ucl.ac.uk.
University College London · GBGeneral University Hospital in Prague · CZCharles University · CZCzech Academy of Sciences, Institute of Molecular Genetics · CZMoorfields Eye Hospital · GBUniversity of Oxford · GB

Funding

Medical Research Council MC_PC_15018Wellcome TrustWellcome Trust 092621
6 · The paper itself

Abstract

Congenital hereditary endothelial dystrophy 1 (CHED1) and posterior polymorphous corneal dystrophy 1 (PPCD1) are autosomal-dominant corneal endothelial dystrophies that have been genetically mapped to overlapping loci on the short arm of chromosome 20. We combined genetic and genomic approaches to identify the cause of disease in extensive pedigrees comprising over 100 affected individuals. After exclusion of pathogenic coding, splice-site, and copy-number variations, a parallel approach using targeted and whole-genome sequencing facilitated the identification of pathogenic variants in a conserved region of the OVOL2 proximal promoter sequence in the index families (c.-339_361dup for CHED1 and c.-370T>C for PPCD1). Direct sequencing of the OVOL2 promoter in other unrelated affected individuals identified two additional mutations within the conserved proximal promoter sequence (c.-274T>G and c.-307T>C). OVOL2 encodes ovo-like zinc finger 2, a C2H2 zinc-finger transcription factor that regulates mesenchymal-to-epithelial transition and acts as a direct transcriptional repressor of the established PPCD-associated gene ZEB1. Interestingly, we did not detect OVOL2 expression in the normal corneal endothelium. Our in vitro data demonstrate that all four mutated OVOL2 promoters exhibited more transcriptional activity than the corresponding wild-type promoter, and we postulate that the mutations identified create cryptic cis-acting regulatory sequence binding sites that drive aberrant OVOL2 expression during endothelial cell development. Our data establish CHED1 and PPCD1 as allelic conditions and show that CHED1 represents the extreme of what can be considered a disease spectrum. They also implicate transcriptional dysregulation of OVOL2 as a common cause of dominantly inherited corneal endothelial dystrophies.

Indexed as

AllelesMutationPromoter Regions, GeneticBase SequenceCorneal Dystrophies, HereditaryDNAFemaleHumansMalePedigreeSequence Homology, Nucleic AcidTranscription FactorsDNAOvol2 protein, humanTranscription Factors

Identifiers

PMID26749309
PMCPMC4716680
OpenAlexW2231402434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.